Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 0.82 |
| ▸ | MMP9 | P14780 | 9/20 | 0.82 |
| ▸ | MMP3 | P08254 | 8/20 | 0.82 |
| ▸ | MMP13 | P45452 | 8/20 | 0.82 |
| ▸ | MMP1 | P03956 | 7/20 | 0.82 |
| ▸ | MMP7 | P09237 | 7/20 | 0.82 |
| ▸ | ADAMTS4 | O75173 | 5/20 | 0.82 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.68 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.68 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.68 |
| ▸ | MMP14 | P50281 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973093 | 1.00 | MMP2 (0.82) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL21451101 | 1.00 | MMP2 (0.82) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4653257 | 0.90 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL32691806 | 0.90 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1750956 | 0.90 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL8648587 | 0.88 | SLC1A2 (0.76) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6446613 | 0.86 | MMP9 (0.91) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4588942 | 0.86 | MMP9 (0.91) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL3964630 | 0.86 | MMP9 (0.91) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6797440 | 0.86 | MMP2 (0.72) | MMP2MMP9MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107602454-B | Sulfonamide compound and preparation method and application thereof | 佛山科学技术学院 | 2020-12-01 | — | — | CN | claimed |
| US-20040062773-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES INC. | 2004-04-01 | — | — | US | claimed |
| EP-0784469-B1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 2004-03-24 | — | — | EP | claimed |
| US-6610329-B2 | Using acylated amino acid as carrier | EMISPHERE TECHNOLOGIES INC. | 2003-08-26 | — | — | US | claimed |
| US-20020001591-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES, INC. | 2002-01-03 | — | — | US | claimed |
| US-5958457-A | MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-09-28 | — | — | US | claimed |
| EP-0784469-A4 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0784469-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996012474-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-05-02 | — | — | WO | claimed |
| US-11040958-B2 | Triazole antimicrobial derivative, pharmaceutical composition and use thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-06-22 | — | — | US | disclosed |
| CN-107602454-B | Sulfonamide compound and preparation method and application thereof | 佛山科学技术学院 | 2020-12-01 | — | — | CN | disclosed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20020001591-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES, INC. | 2002-01-03 | — | — | US | disclosed |
| US-5958457-A | MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5663174-A | ANTIINFLAMMATORY AGENTS, INHIBITOR OF KINASES, ANTIARTHRITIC AGENTS | PHARNO-WEDROPHARM GMBH (DE) | 1997-09-02 | — | — | US | disclosed |
| EP-0602028-B1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO WEDROPHARM GMBH (DE) | 1996-01-17 | — | — | EP | disclosed |
| EP-0602028-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | PHARNO WEDROPHARM GMBH (DE) | 1994-06-22 | — | — | EP | disclosed |
| WO-1993005014-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO-WEDROPHARM GMBH (DE) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020001591-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | MMP2 2444/4885MMP9 2979/4885MMP3 2033/4885 |
| US-20040062773-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | MMP2 2444/4885MMP9 2979/4885MMP3 2033/4885 |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | MMP2 1734/4885MMP9 3044/4885MMP3 1766/4885 |
| US-11040958-B2 | Triazole antimicrobial derivative, pharmaceutical composition and use thereof | SLCO1B3, CYP3A43, GSK3B | MMP2 2064/4885MMP9 2947/4885MMP3 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.